Virtual ACC 2020 | ISCHEMIA: Quality of Life, Not a Soft Endpoint

In the general study, an invasive strategy followed by revascularization (when necessary) vs. an initially conservative strategy with OMT resulted similar in patients with stable CAD with moderate to severe ischemia. A secondary end point of this analysis were angina symptoms and quality of life.

ACC 2020 Virtual | ISCHEMIA: la calidad de vida no es un punto blando

Angina symptoms, functional activity and quality of life were assessed with the Seatle Angina Questionaire (SAQ) at randomization, 45 days, 6 months and every 6 months thereafter. Data were obtained on the 2295 patients randomized to the invasive strategy and on 2322 from the conservative strategy. The SAQ scores from 0 to 100 points where 100 is the healthiest.

At baseline, 35% of patients did not report any angina symptoms in the last month. The SAQ score improved with both strategies, especially at early follow-up, and levelled off later on. This improvement resulted superior with the invasive strategy, even for the general population, that included more than one third of patients with no angina (which could cancel out the difference).


Read also: Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM.


If we consider the most symptomatic (daily angina or at least once a month) vs. patients with no angina, the difference in favor of the invasive strategy becomes more marked. 

Conclusion

Patients randomized to an invasive strategy with eventual randomization showed symptom improvement superior vs. OMT. This significant difference, though modest in the general population (35% asymptomatic at randomization), increases the more symptomatic the patients are at baseline. 

ischemia-sintomas

Original Title: Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.

Reference: John A. Spertus et al. N Engl J Med 2020, article in press. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....